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Abstract
Purpose The duodenum as primary site for gastrointestinal
stromal tumors (GISTs) is rare and mitotic rate, tumor size,
type of mutation and number of chromosomal aberrations
have prognostic implications.
Methods We analyzed the outcome of 13 patients with
duodenal GISTs who underwent surgical tumor resection.
Either segmental duodenectomy or pylorus-preserving duo-
denopancreatectomy was performed. The tumors were his-
topathologically examined and the risk of progression was
assessed based on tumor size and mitotic count. Additionally,
mutation analysis of the KIT and PDGFRA receptor tyrosine
kinase genes and comparative genomic hybridization (CGH)
were performed in all cases.
Results Eight patients underwent segmental duodenectomy
and five patients were treated with pylorus-preserving duo-
denopancreatectomy. None of the five GISTs with low or no
risk for malignancy according to the Miettinen classification
developed tumor progress. In contrast, five of eight cases
(62.5%) with high-risk tumors revealed tumor progress, and
four of these patients died (50%). The median overall survival
for all patients was 66 months, and the median disease-free
survival 41 months. The operative procedure and type of
mutation did not correlate with long-term survival. CGH
analysis displayed −15q in 12/13 tumors, and −1p in 11/13
cases as characteristic chromosomal aberrations for intestinal
origin. Notably, −22q was present in three of four cases with
tumor progress.
Conclusions Both segmental duodenectomy and pylorus-
preserving duodenopancreatectomy are appropriate options
to treat duodenal GIST and should be implemented depend-
ing on resectability and the patient's performing state. The
Miettinen classification and CGH findings correlate with the
clinical course.
Keywords GIST. Duodenum .KITmutation . PDGFRA
mutation . Comparative genomic hybridization
Introduction
Gastrointestinal stromal tumors (GISTs) are supposed to
arise from the interstitial cells of Cajal or their precursors,
located throughout the muscular wall of the gastrointestinal
tract. They occur at an incidence of 10–20/million per year
and at a median age of 55–60 years [1–4]. They arise mostly
in the stomach (60%), followed by the small intestine (35%)
and rectum, esophagus, omentum, and mesentery (<5%) [2].
Duodenal GISTs account for only <5% but make up 30% of
primary duodenal tumors [5]. Most cases occur sporadically,
but 5% occur in the context of a familial syndrome (i.e.,
neurofibromatosis type 1, Carney triad) [2]. They usually
present with abdominal pain to due obstruction, anemia, or
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gastrointestinal bleeding from a central ulceration. Small du-
odenal GISTs may be incidental findings during gastroscopy.
Grossly, GISTs typically present as a sharply demarcatedmass
lesion without lymphatic spread, arising in the submucosa [6].
Histologically, spindle cell (70%), epithelioid (20%) or mixed
type differentiation can be observed, depending on tumor site
[3]. Tumor size, mitotic activity and anatomic site are current-
ly used to predict malignant courses according to the modified
Miettinen classification [4]. Furthermore, the results of
mutation analysis of the KIT and PDGFRA gene and compar-
ative genomic hybridization (CGH) are employed as addition-
al prognostic factors with impact on diagnosis and therapy [2,
7]. The individualized application of tyrosine kinase inhibitors
in patients with high-risk GISTs, certain cases of intermediate-
risk GISTs, and/or incomplete surgical resection has been
established during the past years. However, the role of surgical
treatment remains important since only complete resection of
primary GISTs is curative [1, 5, 6, 8]. The optimal surgical
Fig. 1 Morphologic findings in
a case of duodenal GIST
(patient 12): endoscopy
revealed a submucosal mass
lesion in the duodenum covered
by normal duodenal mucosa
(a arrow). Grossly, the tumor
measured up to 2.5 cm in size
with sharply defined margins
and a pale-white, solid cut
surface (b). Histologically, the
tumor was of spindle cell
differentiation without cellular
atypia (c hematoxylin–eosin
stain) and showed marked
expression of CD117 (cKIT, d)
(×100)
Fig. 2 Kaplan–Meier estimator
demonstrates overall (a) and
disease-free survival (b) for the
13 patients with duodenal GIST
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technique for duodenal GISTs remains to be determined [1, 5,
6, 8–13]. Therefore, a comprehensive risk assessment with
regard of patient outcome is necessary to compare the bene-
ficial effects of limited or major surgery for duodenal GISTs.
The purpose of this study was to compare the efficacy of
duodenal segmentectomy and pylorus-preserving duodeno-
pancreatectomy, and (neo-) adjuvant therapy in 13 primary
duodenal GISTs with regard of recurrence rate and survival.
Materials and methods
Patients and tumor specimens
Thirteen patients including 7 men and 6 women with a mean
age of 69.4 years (range, 58–75 years), who underwent
surgical resection of duodenal GISTs, were included in this
study. Formalin-fixed and paraffin-embedded tumor sam-
ples were examined. Immunohistochemical staining with
CD117 (cKIT; Dako, Glostrup, Denmark), PDGFRA (Neo
Markers, Fremont CA, USA), CD34 (Neo Markers),
smooth-muscle actin (Zytomed Systems, Berlin, Germany),
desmin (Invitrogen, Berlin, Germany), S-100 (Neo Markers),
and Ki67 (Zytomed Systems) was performed in all cases
(Fig. 1). Assessment of maximal tumor size, histologic growth
pattern, and mitotic count in 50 high power fields (HPFs) was
performed independently of clinical variables. The malignant
potential was estimated based on tumor size, mitotic count,
and location according to the updated AFIP criteria pub-
lished in 2006 by Miettinen and Lasota [4]. Survival
data could be obtained for all patients by reviewing the clinical
records and direct communication with the attending physi-
cians. The surgical procedure, including segmental duodenec-
tomy or pylorus-preserving partial duodenopancreatectomy
according to Traverso-Longmire was registered. Based on
tumor size and site, the decision between both operative
procedures was made intraoperatively. Additionally, preoper-
ative and postoperative therapy with tyrosine kinase inhibitors
was assessed. The ethical committee of the University Medi-
cal Center Göttingen, Germany, approved of the experiments
performed in this study (No. 26/12/10).
Mutation analysis
Mutation analysis of KIT exons 9, 11, 13, and 17, as well as
PDGFRA exons 12, 14, and 18, was performed using direct
sequencing of PCR products as described previously [14].
Comparative genomic hybridization
CGH from formalin-fixed and paraffin-embedded tumor
tissue specimens was performed essentially as described
previously [7].
Statistical analysis
All statistical analysis was performed by using the software
program Statistica 9.1 (StatSoft, Hamburg, Germany).
Disease-free survival and overall-survival were estimated
by the Kaplan–Meier method. The groups were compared
with the non-parametric log–rank test.
Fig. 3 Kaplan–Meier estimator
shows the overall survival (a)
and disease-free survival (b) for




Table 1 The perioperative complications of duodenal segmentectomy
and pylorus-preserving duodenopancreatectomy (Traverso-Longmire)
are demonstrated




Hypoxic encephalopathy from unknown
respiratory failure (1)
Cardiac arrhythmia (8, 10)
Anastomotic leakage, secondary Traverso-
Longmire after 13 days (11)
Insulin-dependent diabetes mellitus (11)
Stenosis of biliodigestive anastomosis (11)
Traverso-Longmire Insulin-dependent diabetes mellitus (2)
Impaired healing, wound revision; infected
bilioma (5)
Pancreas fistula (9, 13), impaired healing (9)
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Results
Follow-up
Survival data could be obtained for all patients. None of the
five GISTs with low or no risk for malignancy according to
Miettinen's criteria developed tumor progress. In contrary,
five of the eight cases with high risk of malignancy revealed
tumor progress (62.5%) and four of these patients died
(50%). Overall survival and disease-free survival are demon-
strated in Fig. 2 with a median overall survival of 66 months
and a median disease-free survival of 41 months.
Surgical procedures included segmental duodenectomy in
eight patients, one of which was treated with secondary
pylorus-preserving duodenopancreatectomy due to anasto-
motic leakage and primary pylorus-preserving duodenopan-
createctomy according to Traverso-Longmire in five patients.
There was no significant survival benefit for one or the other
surgical approach regarding overall survival (P00.6993) or
recurrence-free survival (P00.8629) (Fig. 3). One of the
patients with segmental duodenectomy died within the first
30 days due to cardiac arrhythmia. In contrast, none of the
patients with duodenopancreatectomy died. The postoperative
complications are listed in Table 1.
One patient (patient 6) presented with a synchronous
gastric GIST of 1.5 cm size and spindle cell differentiation.
The presence of a KIT exon 11 mutation (c.1648_1662del;
p.K550_E554del) and chromosomal losses at 14q and
22q suggested a synchronous primary gastric GIST rather
than a metastasis. Both tumors were resected and the
patient received imatinib for 3 years. After 71 months,
the patient had no evidence for relapse. One patient
(patient 5) had a synchronous liver metastasis, which
was treated three times by radiofrequency ablation and
hemihepatectomy after 53 months. The primary reason
for the operative intervention and resection of the GIST
in this case was the impairment of food passage. At this
time (2002), neoadjuvant therapy was not yet considered.
Subsequently, the patient was treated with imatinib
(400 mg/d) for 4 years followed by sunitinib (50 mg/d)
and survived 69 months. Three patients [2, 4, 7] devel-
oped liver metastases at 19, 29, and 59 months after
resection of the primary tumor, respectively. Patient 2 is
still alive at 133 months, patient 4 died after 48 months,
and the patient 7 is still alive at 62 months. There was,
however, no significant difference in the overall survival
for patients with and without synchronous liver metasta-
ses (P00.6184). Two patients [1, 2] had local tumor
recurrence after 41 and 19 months, the former of which
survived 42 months, and the latter was operated for local
recurrence (R2), received subsequently chemotherapy
with adriamycin/ifosfamide (four cycles) (see Table 2)
and is still alive at 133 months under imatinib therapy
(400 mg/day). The overall survival in the seven patients
without any evidence of tumor recurrence was not statis-
tically different from the patients with evidence for
remaining/recurrent GIST (P00.4816). Two patients [11,
13] received preoperative (i.e., neoadjuvant) treatment
with imatinib. Patient 11 was treated with 400 mg/day
imatinib for 6 months, and patient 13 (with an exon 9
mutated GIST) received 800 mg/day for 3 months in order to
reduce tumor size and allow complete surgical resection
(Table 2).
Clinicopathological characteristics
Table 2 summarizes the clinicopathological characteristics
for 13 patients with duodenal GISTs. The mean age was
69.4 years, and there was no significant correlation be-
tween age (≤71 vs. >71 years; P00.9139) and tumor
recurrence. The mean tumor size was 7.4 cm (range 1.8–
15 cm). There was no significant correlation between
tumor size and tumor recurrence (≤10 vs. >10 cm; P0
0.2141). Grossly, the tumors were sharply demarcated
without infiltrative growth (Fig. 1). Histologically, 12
tumors were of spindle cell differentiation, and one tumor
was of mixed type differentiation combining spindle cell
and epithelioid areas. There was no significant correlation
between the histologic subtype (spindle cell vs. mixed
type) and tumor recurrence (P00.3618). Immunohisto-
chemically, all tumors expressed CD117, four tumors
PDGFRA, ten tumors CD34, eight tumors smooth-
muscle actin, one tumor desmin, and S-100 was positive
only in the intermixed dendritic cells. The mitotic rate per
50 HPFs ranged from 0 to 100 (mean 16/50 HPFs). The
risk of malignant behavior according to Miettinen resulted
in one case with no risk, four cases of low risk and the
Fig. 4 Kaplan–Meier estimator demonstrates overall survival for the
13 patients with duodenal GIST comparing low-risk vs. high-risk
duodenal GIST
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remaining eight cases with high-risk potential [4]. There
was no significant association of mitotic rate and recurrence
rate (≤5 vs. >5 mitoses/50 HPFs; P00.8264). There was a
tendency towards differences in the overall survival for
patients with high-risk potential compared to patients with
low-risk potential, however, due to the small patient number
the findings, were not statistically significant (P00.0556)
(Fig. 4).
Mutation analysis
Mutation analysis of the KIT and PDGFRA gene was
performed in all cases (Table 3). The total number of
mutations per each examined exon for all patients is
summarized in Fig. 5. The number of mutations ranged
between 0 and 2 mutations per tumor. Three tumors
revealed no mutations (so-called “wild-type” GISTs),
and ten tumors displayed one mutation. The polymor-
phism V824V was present in six cases, and a silent KIT
exon 17 mutation in one case. KIT exon 9 harbored the
A502_Y503 duplication in all four cases, KIT exon 11
displayed the point mutations W557G, V559D, V560E,
and the deletion W557_K558. KIT exon 13 and PDGFRA
exon 12 and 14 revealed no mutations.
Comparative genomic hybridization
CGH was performed in all cases (Table 3). The chromosom-
al gains and losses of all patients are summarized in Fig. 6.
The mean number of aberrations was 5.4 (range 0–13)
including a mean of 1 gain (range, 0–3), 4.3 losses (range,
0–10), and 0.16 amplifications (range, 0–1). Patient 6 dis-
played no chromosomal imbalances. The most frequently
observed aberrations comprised losses at 1p (11/13 cases,
84.6%), losses at 15q (12/13 cases, 92.3%), and losses at
22q (5/13 cases, 38.4%). Less than or five losses were not
associated with a better survival rate as compared to >5
losses (P00.0799) (Fig. 7).
Discussion
Only 4–5% of all GISTs are located in the duodenum [4, 6,
13]. As reported, abdominal pain, anemia, and gastrointes-
tinal bleeding are usually the most common symptoms [13].
Due to the absence of lymph node metastases or infiltrative
growth of GISTs, local excision is usually sufficient, but
when the tumor is located close to important anatomical
structures, pylorus-preserving duodenopancreatectomy
may become necessary [6].
We reviewed the outcome of 13 patients, who underwent
surgery for duodenal GIST by segmental duodenectomy and
pylorus-preserving duodenopancreatectomy.
Based on the criteria proposed by Miettinen et al. [4] for
the estimation of the risk of progression, the tumors in the
present study were classified as no risk in one case (7.7%),
low risk in four cases (30.8%), and high risk in nine cases
(69.2%). Six tumors displayed more than five mitoses/50
HPF, thus automatically qualifying as high-risk tumors. Of
the seven patients with ≤5 mitoses/50 HPF, two were
Fig. 5 Results of KIT exon 9,
11, 13, and 17 and PDGFRA
exon 12, 14, and 18 mutation
analyses in 13 duodenal
gastrointestinal stromal tumors
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classified as high risk due to the large tumor size of >5 cm.
The mean tumor size of 7.4 cm in the present study is in
accordance with previous findings in 90 primary and meta-
static duodenal GISTs in which the mean tumor size was
6 cm (range 1.5–31 cm) [13]. The reported prevalence of
high-risk cases ranges from 23 to 44% in GISTs of all
locations [15–17]. The large number of high-risk tumors in
the present study may be explained by both, the location, as
no intermediate stage is defined for duodenal GISTs and
because of the high mitotic rate in some of our cases. As
expected, only the high-risk cases developed recurrence (5/
8 cases) as compared to none of the patients with low-risk
GIST (0/5). In the present study, 38.5% of the patients
developed localized or distant tumor progress. These find-
ings are similar to previous findings in duodenal GISTs, in
which recurrence was reported to occur in 35% [13]. Fur-
thermore, four of eight patients with high-risk GIST died
compared to none of the patients with low-risk tumors (0/5),
indicating an impact of the Miettinen classification on long-
term survival, even though it was not statistically significant
(P00.0556) in our cohort due to the small number of cases.
Our findings are in accordance with a previous study on
duodenal GISTs [11], in which the authors identified the
classification as high-risk GIST as the only predictor for
disease recurrence [11]. In a study on 90 duodenal GISTs,
however, only the mitotic rate predicted relapse in multivar-
iate analysis [13]. Furthermore, in univariate analyses, age
and ECOG performance state had an impact on overall
survival, and necrosis, spindle cell morphology, tumor size,
and mitotic rate were predictors for relapse [13]. In the
present study, the ECOG state and necrosis were not
assessed. Age, spindle cell differentiation, tumor size, and
mitotic rate were not associated with a higher rate of
recurrence.
Mutations of the KIT or PDGFRA gene have been iden-
tified as primary steps in tumorigenesis of GISTs [7]. In this
study, ten tumors (76.9%) showed mutations of the KIT
gene, and two tumors (15.4%) were “wild-type” GISTs.
Four patients had an exon 9 mutation (30.8%) and six
patients an exon 11 mutation (46.2%) [3, 18, 19]. KIT exon
Fig. 7 Kaplan–Meier estimator demonstrates overall survival for the
13 patients with duodenal GIST comparing the cases with ≤5 and >5
chromosomal losses as detected by comparative genomic hybridization
Fig. 6 Chromosomal
imbalances in 13 duodenal
gastrointestinal stromal tumors
as detected by comparative
genomic hybridization are
shown as bright gray (gains),
black (losses), and dark gray
bars (amplifications) for each
chromosome. Losses at 1p, 15q,
and 22q are among the most
frequently observed aberrations
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9 mutations are reported to occur in 13–15%, exon 11
mutations in 66.1–70% (76% in duodenal GISTs), and
wild-type GISTs making up approximately 10–15% [3, 13,
18, 20]. Thus, in the present study, KIT exon 9 mutations
were observed slightly more frequent and exon 11 mutations
less frequent than reported previously in the literature for
GISTs. KIT exon 11 mutations are known to harbor a less
favorable prognosis than KIT exon 9 mutations and are at
high metastatic risk [20]. Also, point mutations are generally
associated with a clinically more favorable course as com-
pared to deletions [21]. However, exon 11 mutations show a
better response to targeted treatment with imatinib mesylate
than do exon 9 mutations [20].
Losses at 1p, 15q and 22q, as detected by CGH, are
imbalances typical of small intestinal GISTs, being observed
in 88%, 59%, and 82% of cases, respectively [22]. Espe-
cially, combined losses at 1p and 15q are described to occur
in 75% of intestinal GISTs [22]. As reported previously,
losses at 22q being present in 75% of our cases with tumor
progress, are associated with an unfavorable cytogenetic
sub-pathway and significantly more additional imbalances
than tumors without −22q, reflecting an increased capacity
for cytogenetic complexity [7]. GISTs with −22q are signif-
icantly more often high-risk tumors, behave clinically ma-
lignant, and have a poorer disease-free survival [7].
In a previous study, GISTs classified as probably benign
or of low malignant potential had a smaller mean number of
aberrations than those evaluated as probably malignant (4.6
versus 7.4) [22]. In our study, the mean number of 5.4
aberrations per tumor indicates that the tumors display a
moderate degree of genetic instability and thus range be-
tween benign and malignant risk potential. Of all 13 tumors,
6 displayed ≥5 aberrations, thus tending towards a rather
instable karyotype with genetic progression. CGH can be
used as helpful additional method to assess the risk of
malignancy or progression in duodenal GISTs and might
help in deciding for or against (neo-) adjuvant treatment.
Concerning the operative procedure, the authors of pre-
vious studies preferred segmental duodenectomy to duode-
nopancreatectomy since this procedure has a lower
operative morbidity while providing comparable oncologi-
cal results [5, 6, 9, 11–13, 23]. However, in one of these
studies, only tumors with <5 mitoses/50 HPFs, a mean size
of 3.5 cm, and very low/low/intermediate risk were included
and treated with limited surgery [12]. In smaller tumors,
measuring ≤5 cm in size, limited resection seems to be
favorable. Duodenal GISTs of >5 cm are already classified
as high-risk tumors according to the Miettinen classifica-
tion, irrespective of the mitotic count. In these cases and in
locally advanced tumors neoadjuvant treatment is an option
to reduce tumor size [13]. Adjuvant therapy should follow.
However, in our study, four high-risk patients did not re-
ceive adjuvant therapy—as at the time, adjuvant therapy (i.e.,
therapy within the first weeks after operation) was not gener-
ally performed after complete resection of the tumor. To our
knowledge, two of these four patients died of tumor progres-
sion. In our study, one of the patients, who underwent
segmental duodenectomy, died within 30 days after the oper-
ation in contrast to none of the patients with duodenopancrea-
tectomy, but no significant advantage of one or the other
operative method was detectable.
In conclusion, complete surgical resection is the only
curative treatment for duodenal GISTs. Since both, limited
and extended surgery yield comparable survival rates, tumor
size and location in regard to the papilla of Vater [11],
associated diseases and the patient's performing state should
be considered when deciding between segmental duodenec-
tomy and pylorus-preserving duodenopancreatectomy. If
duodenopancreatectomy is necessary, it has no impact on
overall survival and recurrence rates in experiences centers.
Neoadjuvant imatinib treatment might be an option and is
tested in clinical studies. The risk stratification according to
the Miettinen criteria and the assessment of genomic aber-
rations by CGH are helpful in predicting the biological
behavior and clinical course of duodenal GISTs.
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